MAJIC trial

Chief investigator - Professor Claire Harrison, Guys and St Thomas’ NHS Foundation Trust
A phase II study of ruxolitinib (INCB424) in patients with high risk polycythaemia vera or essential thrombocythaemia resistant to or intolerant of standard therapy
Award start date: 01 Aug 2011
Recruitment start date: 01 Aug 2012
Award duration: 7 years (84 months)

This study is for people with a type of blood disorder called myeloproliferative neoplasms (MPN) that causes the bone marrow to produce too many blood cells. This includes: polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF).

People with PV produce too many red blood cells, causing the blood to become thicker than normal. ET occurs when there are too many platelets in the blood, which can cause the blood to clot. People with MF have an overactive bone marrow, which develops scar tissue (known as fibrosis). The scar tissue builds up inside the bone marrow and blood cells can’t develop properly causing other complications including anaemia.

Doctors usually treat MPNs with a chemotherapy called hydroxycarbamide, which works by stopping the cancer cells making and repairing DNA. But some people can’t take hydroxycarbamide and sometimes the MPN stops responding to it.

Researchers think that a drug called ruxolitinib may help people with high risk PV and high risk ET. Ruxolitinib is a JAK inhibitor, and works by blocking the abnormal JAK signalling associated with changes to the JAK2 gene found in blood cells in people with MPN. By inhibiting this pathway, ruxolitinib can stop cancer cells from growing and dividing.

The aims of this trial were to:

  • See how well ruxolitinib works for people with PV and ET who can’t have hydroxycarbamide
  • See how safe it is in people with PV and ET

This trial is closed for recruitment, and we hope to update you with the results soon.